» Authors » Christoph Rochlitz

Christoph Rochlitz

Explore the profile of Christoph Rochlitz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 84
Citations 2617
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kurzeder C, Nguyen-Strauli B, Krol I, Ring A, Castro-Giner F, Nuesch M, et al.
Nat Med . 2025 Jan; PMID: 39856336
The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors...
2.
Wallrabenstein T, Oseledchyk A, Daetwyler E, Rochlitz C, Vetter M
Cancers (Basel) . 2023 Oct; 15(20). PMID: 37894320
Patients with endocrine-resistant metastatic breast cancer (MBC) require cytostatic therapy. Single-agent taxanes and anthracyclines, including pegylated liposomal doxorubicin (PLD), are standard treatment options. There are no prospective data regarding optimal...
3.
Meinlschmidt G, Grossert A, Meffert C, Roemmel N, Hess V, Rochlitz C, et al.
JMIR Cancer . 2023 Aug; 9:e38515. PMID: 37639296
Background: Cancer is related to not only physical but also mental suffering. Notably, body image disturbances are highly relevant to cancer-related changes often persisting beyond recovery from cancer. Scalable and...
4.
Grossert A, Meffert C, Hess V, Rochlitz C, Pless M, Hunziker S, et al.
Front Psychol . 2023 Apr; 14:956493. PMID: 37089722
Introduction: Cancer-related impairments often co-occur with bodily disturbances. Body psychotherapy (BPT) can improve bodily wellbeing, yet evidence in cancer survivors is scarce. Hence, we aimed to evaluate whether blended group...
5.
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, et al.
Sci Rep . 2023 Mar; 13(1):3705. PMID: 36879012
Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the...
6.
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, et al.
J Geriatr Oncol . 2022 Sep; 14(1):101372. PMID: 36127284
Introduction: Standard-dose eribulin mesylate (1.4 mg/m d1 + 8) achieves clinical benefit rates of 26%-52% in patients with metastatic breast cancer (mBC). <10% of patients in the registration trial were ...
7.
Ehrbar V, Scherzinger L, Urech C, Rochlitz C, Tschudin S, Sartorius G
Urol Oncol . 2022 Jun; 40(8):385.e19-385.e25. PMID: 35764444
Introduction: As fertility may be impaired due to gonadotoxic cancer treatment, fertility preservation should be offered to young cancer patients. Despite affirmative guidelines, sperm cryopreservation rates are still unsatisfying. Objective:...
8.
Diamantopoulou Z, Castro-Giner F, Schwab F, Foerster C, Saini M, Budinjas S, et al.
Nature . 2022 Jun; 607(7917):156-162. PMID: 35732738
The metastatic spread of cancer is achieved by the haematogenous dissemination of circulating tumour cells (CTCs). Generally, however, the temporal dynamics that dictate the generation of metastasis-competent CTCs are largely...
9.
Scheidmann M, Castro-Giner F, Strittmatter K, Krol I, Paasinen-Sohns A, Scherrer R, et al.
Cancer Res . 2021 Dec; 82(4):681-694. PMID: 34916221
Significance: A loss-of-function CRISPR screen in human CTC-derived xenografts identifies genes critical for individual steps of the metastatic cascade, suggesting novel drivers and treatment opportunities for metastatic breast cancers.
10.
Merlo P, Rochlitz C, Osthoff M
Case Rep Oncol . 2021 Mar; 14(1):73-77. PMID: 33776685
A 78-year-old man with metastatic prostate cancer was referred to the hospital 5 weeks after the initiation of systemic therapy with goserelin (GnRH agonist) because of a significant increase in...